Kway Jasmine 4

What Happened
Jasmine Kway, CEO of VolitionRx’s Singapore operations, was granted 173,000 restricted stock units (RSUs) on February 26, 2026. The filing reports an acquisition price of $0.00 (awarded in lieu of cash compensation). This is an award (not a market purchase or sale) and does not represent an immediate cash transaction or open‑market trade.

Key Details

• Transaction date: 2026-02-26; Form 4 filed 2026-02-27.
• Transaction type/code: Award/Grant (A). Reported acquisition price: $0.00; reported total value: $0 (per Form 4 reporting conventions).
• Grant size: 173,000 RSUs under the Issuer’s 2024 Stock Incentive Plan.
• Vesting schedule: RSUs are earned in 12 approximately equal monthly installments beginning March 1, 2026; once earned they remain subject to additional time‑based vesting in a single installment on February 26, 2027. Continued service is required for each earn and vest date.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: RSUs were awarded in lieu of cash compensation owed to the reporting person (see footnote F1).
• Timeliness: Filed the day after the grant date (no late‑filing indication on the Form 4).

Context
RSUs convert to actual shares only when they are earned and then vest; because these units are subject to both monthly earning and a subsequent time‑based vest on Feb 26, 2027, they do not provide immediate liquidity and are a retention/compensation measure rather than an instantaneous market signal. Awards in lieu of cash are common for conserving cash or aligning executive pay with equity.